Rheumatoid arthritis associated autoantibodies in patients with synovitis of recent onset.
STATEMENT OF FINDINGS: An inception cohort of 238 patients having peripheral joint synovitis of less than 12 months duration was evaluated clinically and followed prospectively for 1 year to determine the clinical significance of a number of rheumatoid arthritis (RA) associated autoantibodies. Serum samples collected at the time of the initial evaluation were tested for rheumatoid factor (RF) and antibodies to Sa (anti-Sa), RA-33, (pro)filaggrin [antifilaggrin antibody (AFA)], cyclic citrullinated peptide (anti-CCP), calpastatin, and keratin [antikeratin antibody (AKA)]. RF had a sensitivity of 66% and a specificity of 87% for RA. Anti-Sa, AFA, and anti-CCP all had a specificity of more than 90%, but a sensitivity of less than 50% for this diagnosis. Overall, there was a high degree of correlation between AFA, AKA, anti-Sa or anti-CCP, this being highest between anti-Sa and anti-CCP (odds ratio, 13.3; P < 0.001). Of the 101 patients who were positive for at least one of these four autoantibodies, 57% were positive for only one. Finally, anti-SA identified a subset of predominantly male RA patients with severe, erosive disease. Anti-SA, AFA and anti-CCP are all specific for early RA but, overall, have little additional diagnostic value over RF alone. Although these antibodies may preferentially recognize citrullinated antigens, the modest degree of concordance between them in individual patient sera suggests that it is unlikely a single antigen is involved in generating these responses.
Goldbach-Mansky
R
R
Arthritis and Rheumatism Branch, National Institute of Arthritis and Musculoskelatal and Skin Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
Lee
J
J
McCoy
A
A
Hoxworth
J
J
Yarboro
C
C
Smolen
J S
JS
Steiner
G
G
Rosen
A
A
Zhang
C
C
Ménard
H A
HA
Zhou
Z J
ZJ
Palosuo
T
T
Van Venrooij
W J
WJ
Wilder
R L
RL
Klippel
J H
JH
Schumacher
H R
HR
El-Gabalawy
H S
HS
D000208:Acute Disease; D000328:Adult; D000918:Antibody Specificity; D001172:Arthritis, Rheumatoid / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*; D001323:Autoantibodies / Q000097:blood*; D002135:Calcium-Binding Proteins / Q000276:immunology; D002956:Citrulline / Q000276:immunology; D003066:Coenzyme A Ligases; D015331:Cohort Studies; D000939:Epitopes / Q000276:immunology; D005260:Female; D000091344:Filaggrin Proteins; D006650:Histocompatibility Testing; D006801:Humans; D007381:Intermediate Filament Proteins / Q000276:immunology; D007633:Keratins / Q000276:immunology; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000276:immunology; D011237:Predictive Value of Tests; D011506:Proteins / Q000276:immunology; D012217:Rheumatoid Factor / Q000097:blood; D016036:Seroepidemiologic Studies; D013585:Synovitis / Q000175:diagnosis* / Q000453:epidemiology / Q000276:immunology*
D001323:Autoantibodies; D002135:Calcium-Binding Proteins; D000939:Epitopes; C000717249:FLG protein, human; D000091344:Filaggrin Proteins; D007381:Intermediate Filament Proteins; D010456:Peptides, Cyclic; D011506:Proteins; D002956:Citrulline; D007633:Keratins; C033668:calpastatin; D012217:Rheumatoid Factor; C081817:Acsm3 protein, rat; D003066:Coenzyme A Ligases